Shukra Pharmaceuticals Ltd — Important, 07-05-2026: Company Update

Shukra Pharmaceuticals has filed its annual secretarial compliance report for the past financial year, indicating generally strong adherence to corporate governance standards. The company successfully raised capital by issuing 46.43 lakh convertible equity warrants to promoters at Rs. 34 each, totaling Rs. 15.79 crore. Strategic expansion is evident with the incorporation of four new subsidiaries: Shukra Diabetes Technologies, Shukra Healthtech, Shukra Robotics, and Shukra WoundCare. Additionally, there were changes in the board of directors and a new statutory auditor was appointed. Minor compliance delays from a previous period resulted in small fines, which have been settled.